Advertisement

Non-high density lipoprotein cholesterol and coronary events during long-term statin treatment

      Non-high density lipoprotein cholesterol (non-HDL-C=total cholesterol−HDL-C) was used as a lipid parameter during the 1990s [
      • Pedersen T.R.
      • Olsson A.G.
      • Faergeman O.
      • Kjekshus J.
      • Wedel H.
      • Berg K.
      Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian simvastatin survival study (4S).
      ], but it has been officially established as a secondary treatment target, mainly in patients with high triglyceride levels, by the Adult Treatment Panel (ATP) III of the National Cholesterol Educational Program (NCEP) in 2001 [

      Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J. Am. Med. Assoc. 2001;285:2486–2497.

      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pedersen T.R.
        • Olsson A.G.
        • Faergeman O.
        • Kjekshus J.
        • Wedel H.
        • Berg K.
        Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian simvastatin survival study (4S).
        Circulation. 1998; 97: 1453-1460
      1. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J. Am. Med. Assoc. 2001;285:2486–2497.

        • Cui Y.
        • Blumenthal R.S.
        • Flaws J.A.
        • Whiteman M.K.
        • Langenberg P.
        • Bachorik P.S.
        Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality.
        Arch. Intern. Med. 2001; 161: 1413-1419
        • Frost P.H.
        • Havel R.J.
        Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy.
        Am. J. Cardiol. 1998; 81: 26B-31B
        • Bittner V.
        • Hardison R.
        • Kelsey S.F.
        • Weiner B.H.
        • Jacobs A.K.
        • Sopko G.
        Non-high-density lipoprotein Cholesterol levels predict five-year outcome in the bypass angioplasty revascularization investigation (BARI).
        Circulation. 2002; 106: 2537-2542
        • Lu W.
        • Resnick H.E.
        • Jablonski K.A.
        • Jones K.L.
        • Jain A.K.
        • Howard W.J.
        Non-HDL Cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The Strong Heart Study.
        Diabetes Care. 2003; 26: 16-23
        • Athyros V.G.
        • Papageorgiou A.A.
        • Mercouris B.R.
        • Athyrou V.V.
        • Symeonidis A.N.
        • Basayannis A.C.
        Treatment with atorvastatin to the national cholesterol educational program goals versus usual care in secondary coronary heart disease prevention: The Greek atorvastatin and coronary-heart-disease evaluation (GREACE) study.
        Curr. Med. Res. Opin. 2002; 18: 220-228